glp 1 agonist medicine GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders Unlocking the broad health benefits

Our survey shows that exercise rates among GLP-1 users are declining, which raises concerns about long-term health outcomes

113 Patients with active UC and CD had higher amounts of bioactive GLP-2 than healthy controls, according to a study by Xiao et al

Consistent with this concept, GLP-1RAs have been shown to directly modulate immune responses by reducing the secretion of key pro-inflammatory cytokines such as IL-6 and TNF-, which are central drivers of inflammation in both PsO and PsA (70, 71)

Mimics the complementary effects of diet and exercise, with GLP-1 suppressing appetite and glucagon increasing energy expenditure

Alosaimi, Atheer Alghamdi, Taif Alkhashi, Salman S

Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S